Multi-gene expression prognostic assays are commonly used to aid clinical decision-making in early-stage ER-positive, HER2-negative breast cancer as they provide complementary prognostic information to clinico-pathologic features [3]. The gene discussed is ERBB2; the disease is breast cancer.